■毫无疑问,桥本甲状腺炎和格雷夫斯病都是自身免疫性甲状腺疾病(AITDs),但是抗核抗体(ANA)和AITDs之间的关系研究很少。评估甲状腺自身抗体水平与ANA阳性之间的关联,以评估ANA在AITDs中的作用。
我们使用在我们医院注册的1,149,893名患者和在国家健康和营养调查数据库中注册的53,021名患者的数据进行了分析。我们关注甲状腺过氧化物酶抗体(TPOAb)/ANA数据的患者,TPOAb/免疫球蛋白G(IgG),促甲状腺激素(TSH)受体抗体(TRAb)/ANA,TRAb/IgG,TSH/ANA,或TSH/IgG。
■TPOAb/ANA和TSH/ANA患者的ANA阳性率分别为12.88%和21.22%,分别。在TPOAb/IgG和TSH/IgG数据中,在2.23%和4.06%的患者中检测到高IgG水平(≥15g/L),分别。在不同TPOAb和TSH水平的患者中,ANA阳性率和高IgG比例存在显着差异。TPOAb水平与ANA阳性率和高IgG比例相关,TSH水平与ANA阳性率相关。回归分析显示TPOAb水平与ANA阳性风险或高IgG风险呈正相关,TSH水平和高IgG风险,TSH和ANA阳性风险升高。有TRAb/ANA数据的患者,35.99%为ANA阳性,13.93%的患者有TRAb水平≥1.75IU/L;18.96%的患者有TRAb/IgG数据,16.51%的TRAb水平≥1.75IU/LANA阳性率和高IgG比例在不同TRAb水平之间没有显着差异。TRAb水平,ANA阳性风险和高IgG风险无相关性。
■ANA阳性和高IgG与桥本甲状腺炎有关,但与Graves病无关,这暗示了AITDs背后独特的病理生理机制。
UNASSIGNED: There is no doubt that both Hashimoto thyroiditis and Graves\' disease are autoimmune thyroid diseases (AITDs), but the relationship between anti-nuclear antibody (ANA) and AITDs is poorly studied. The association between thyroid autoantibody levels and ANA positivity was evaluated to assess the role of ANA in AITDs.
UNASSIGNED: We conducted an analysis using data from 1,149,893 patients registered at our hospital and 53,021 patients registered in the National Health and Nutrition Examination Survey databases. We focused on patients with data for thyroid peroxidase antibody (TPOAb)/ANA, TPOAb/immunoglobulin G (IgG), thyroid-stimulating hormone (TSH) receptor antibody (TRAb)/ANA, TRAb/IgG, TSH/ANA, or TSH/IgG.
UNASSIGNED: ANA positivity rates were 12.88% and 21.22% in TPOAb/ANA and TSH/ANA patients, respectively. In TPOAb/IgG and TSH/IgG data, high IgG levels (≥15 g/L) were detected in 2.23% and 4.06% of patients, respectively. There were significant differences in ANA positivity rates and high IgG proportions among patients with different TPOAb and TSH levels. TPOAb level was correlated with ANA positivity rate and high IgG proportion, and TSH level was correlated with ANA positivity rate. Regression analysis showed positive correlations between TPOAb levels and ANA positivity risk or high IgG risk, TSH levels and high IgG risk, and elevated TSH and ANA positivity risk. Of patients with TRAb/ANA data, 35.99% were ANA-positive, and 13.93% had TRAb levels ≥1.75IU/L; 18.96% of patients with TRAb/IgG data had high IgG levels, and 16.51% had TRAb levels ≥1.75IU/L. ANA positivity rate and high IgG proportion were not significantly different among different TRAb levels. TRAb levels, ANA positivity risk and high IgG risk were not correlated.
UNASSIGNED: ANA positivity and high IgG are related to Hashimoto thyroiditis but not Graves\' disease, which implies distinct pathophysiological mechanisms underlying the AITDs.